Successful Treatment of Concurrent Chemoradiotherapy for Stage I Nasal NK/T Cell Lymphoma: A Report of Two Cases

• Published in: Anticancer research 2005-11, Vol.25 (6C), p.4403-4406
• Main Authors: Niibe, Yuzuru, Hayakawa, Kazushige, Kitano, Masashi, Ishiyama, Hiromichi, Nakayama, Meijin, Yao, Kazuo, Okamoto, Makito
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Killer Cells, Natural - pathology; Lymphoma, T-Cell - drug therapy; Lymphoma, T-Cell - pathology; Lymphoma, T-Cell - radiotherapy; Male; Middle Aged; Neoplasm Staging; Nose Neoplasms - drug therapy; Nose Neoplasms - pathology; Nose Neoplasms - radiotherapy
• ISSN: 0250-7005; 1791-7530

Nasal natural killer/T cell (NK/T cell) lymphoma is a rare subtype of lymphomas, being a subtype of non-Hodgkin's lymphoma with a much worse prognosis than other subtypes. One reason for this worse prognosis is that nasal NK/T cell lymphoma is resistant to standard sequential chemoradiotherapy. Thus, we adopted concurrent chemoradiotherapy using a CHOP-like regimen for treating stage I nasal NK/T cell lymphoma. Case 1 was treated with concurrent chemoradiotherapy using 41-Gy irradiation with 12 cycles of the CHOP-like regimen (THP-CVP). Case 2 was treated with concurrent chemoradiotherapy using 50-Gy irradiation with 10 cycles of THP-CVP. In both Case 1 and Case 2, the tumors disappeared after chemoradiotherapy. The Case 1 patient is still alive with 45 months free of relapse. The Case 2 patient is also still alive with 39 months free of relapse. These results suggest that concurrent chemoradiotherapy using a CHOP-like regimen for stage I nasal NK/T cell lymphoma provided sufficient dose intensity and may be a useful treatment option.